Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q2 FY19 results · Jul–Sep 2018
Glenmark Pharmaceuticals reported revenue from operations of ₹2,581.33 crore and net profit of ₹414.00 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,581.33 | — | — | 2,165.62 | +19.2% |
| Other income | 139.88 | — | — | 138.22 | +1.2% |
| Total income | 2,721.21 | — | — | 2,303.83 | +18.1% |
| Profit before tax | 579.59 | — | — | 326.70 | +77.4% |
| Net profit for the period | 414.00 | — | — | 232.99 | +77.7% |
| Attributable to shareholders of the company | 368.14 | — | — | — | — |
| EPS, basic (₹) | 14.67 | — | — | 8.26 | not comparable |
| Net margin (%) | 16.0 | — | 10.8 |
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,679.71 | — | — | 1,618.41 | +3.8% |
| Other income | 226.30 | — | — | 173.65 | +30.3% |
| Total income | 1,906.02 | — | — | 1,792.06 | +6.4% |
| Profit before tax | 875.52 | — | — | 495.36 | +76.7% |
| Net profit for the period | 747.56 | — | — | 397.39 | +88.1% |
| EPS, basic (₹) | 26.49 | — | — | 14.08 | +88.1% |
| Net margin (%) | 44.5 | — | 24.6 |
Consolidated
- Filed with BSE
- 14 Nov 2018, 20:45 IST
- Board meeting
- 13 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2018, 20:45 IST
- Board meeting
- 13 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE